EpiPen-maker Mylan misses on Q3 earnings
AP
That loss was attrubuted to the cost of a proposed$465 million settlement with the U.S. department of Justice and other government agencies.
Mylan posted a net loss of $119.8 million, or 23 cents per share, compared with a profit of $428.6 million, or 83 cents per share, a year ago.
Excluding items, such as the $465 million Department of Justice settlement expense, Mylan said it had adjusted earnings of $1.38 per share. Analysts on average expected $1.45 (vs $1.43) per share, according to Thomson Reuters I/B/E/S.
Mylan noted that EpiPen prescriptions had been rising, but volumes were down because wholesalers weren't purchasing the devices ahead of Mylan's generic authorized generic EpiPen coming soon.
(Reuters reporting by Bill Berkrot; Editing by Chris Reese)
- As Ilya Sutskever announces OpenAI exit, here’s a quick recap of his involvement in Sam Altman's firing last year
- DHFL scam, simplified: Here’s all about the Dheeraj Wadhawan case — allegedly India’s biggest banking loan fraud ever
- India-UK trade pact: Work in progress to resolve pending issues
- 5 most colourful mountains in the world
- Vivo takes the top spot in India: Top smartphone brands in Q1 2024